Information Provided By:
Fly News Breaks for March 20, 2018
MOH
Mar 20, 2018 | 06:16 EDT
Piper Jaffray analyst Sarah James raised her price target for Molina Healthcare to $92 after spending time with management. The company is "ahead of the game in identifying issues and putting the right people in place to fix them," James tells investors in a research note. She thinks communication of this at the May 31 investor day will be a "significant positive catalyst for the stock." The analyst believes Molina's turnaround is progressing and a positive risk/reward is emerging. James reiterates an Overweight rating on the shares and encourages investors to add to positions ahead of the investor day.
News For MOH From the Last 2 Days
MOH
Mar 28, 2024 | 16:23 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MOH
Mar 28, 2024 | 15:22 EDT
What has Wall Street been buzzing about this week? Here are the top 5 Bu-y calls and the top 5 Sell calls made by Wall Street’s best analysts during the week of March 25-28. Find all top-rated... To see the rest of the story go to thefly.com. See Story Here
MOH
Mar 28, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MOH
Mar 28, 2024 | 06:51 EDT
BofA downgraded Molina Healthcare (MOH) to Underperform from Neutral with a $439 price target. The firm, which is concerned that Molina and the Medicaid industry more broadly are likely to face rate pressure after a period of elevated margins, sees a less attractive risk/reward for Molina compared to other insurers the firm covers, the analyst tells investors. Molina is now trading roughly at parity with the firm's top pick in the space, UnitedHealth (UNH), compared to a 22% discount that had been seen over the last five years, helping to underscore the firm's view that "sentiment for Medicaid is nearing a top just at a time when Medicare is reaching a bottom," the analyst added.